Across TCGA pan-cancer cohorts, TMEM129 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TMEM129 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TMEM129 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM129 expression acts as an unfavorable survival marker.
STAD are the cancer types where TMEM129 Mutation most reproducibly stratifies survival.